Group 1 - The A-share cross-border e-commerce sector experienced a significant rise at the beginning of trading, with stocks such as Kuaishangtong and Shengtong Co. hitting the daily limit for gains [1] - Taihu Snow saw an increase of over 9%, indicating strong market interest and performance in the sector [1] - Other companies like Zhongfangbiao and Zhongbai Group also experienced upward movement, reflecting a broader positive trend in the cross-border e-commerce industry [1]

Market Overview - The Shanghai Composite Index is at 3305.11 points, above the annual line, with an increase of 0.80% [1] - The total trading volume of A-shares is 646.819 billion yuan [1] Stocks Breaking Annual Line - A total of 233 A-shares have surpassed the annual line today [1] - Notable stocks with significant deviation rates include: - Jinkai Biological Science and Technology (10.11%) - Disen Power (9.84%) - Hanbo High-tech (8.84%) [1] Stock Performance Details - The top stocks with their respective performance metrics are as follows: - Jinkai Biological: Price increased by 10.32%, turnover rate 13.55%, latest price 33.02 yuan [1] - Disen Power: Price increased by 10.04%, turnover rate 1.77%, latest price 4.93 yuan [1] - Hanbo High-tech: Price increased by 9.42%, turnover rate 3.54%, latest price 15.33 yuan [1] - Other notable stocks include: - Jiashitang (9.97%, 3.57%, 13.13 yuan) - Sanmu Group (9.94%, 7.78%, 3.54 yuan) [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Yongqing Environmental Protection - Dongjian Technology - Aishide [1]

Group 1: Financial Performance - In 2024, the company achieved a revenue of 497.01 million yuan and a net profit of 38.61 million yuan, both showing a significant decline year-on-year [6][7] - In Q1 2025, the company reported a revenue of 176.34 million yuan and a net profit of 47.42 million yuan, indicating a substantial recovery due to prior adjustments and concentrated order deliveries [7] Group 2: Strategic Adjustments - The company has made strategic adjustments in response to adverse international trade policies, enhancing service capabilities and increasing R&D investments [2][3] - To mitigate risks from U.S. tariff policies, the company plans to upgrade its production base in Wisconsin, USA, by expanding capacity and improving service capabilities [3][10] Group 3: Environmental Commitment - In 2024, the company invested 41.50 million yuan in environmental protection, purchasing 14,925,000 kWh of green electricity, resulting in a reduction of CO2 emissions by 13,013,107.50 kg [4][5] Group 4: Market Outlook and Risks - The company acknowledges uncertainties in overseas business due to tariff policies, which may affect order acquisition and delivery cycles [5][8] - The global pharmaceutical market is expected to continue growing, with increasing demand for CDMO services, presenting potential growth opportunities for the company [8][13] Group 5: Shareholder Relations - The company emphasizes its commitment to protecting shareholder interests and will disclose any significant shareholding changes in accordance with regulations [8][13] - A cash dividend of 4 yuan per 10 shares is proposed for 2024, amounting to 48.18 million yuan, which exceeds the net profit for that year [13]

Summary of Key Points Core Viewpoint - The latest financing balance of the ChiNext market is 336.92 billion yuan, showing a decrease of 0.7 billion yuan compared to the previous period, with 19 stocks experiencing a financing balance growth of over 10% and 12 stocks seeing a decline of over 10% [1]. Financing Balance Overview - As of April 24, the ChiNext index fell by 0.68%, with a total margin balance of 337.83 billion yuan, down by 0.7 billion yuan from the previous trading day. The financing balance specifically is 336.92 billion yuan, a decrease of 0.7 billion yuan, while the securities lending balance is 91.3 million yuan, down by 3.22 million yuan [1]. - A total of 417 stocks saw an increase in financing balance, with 19 stocks increasing by more than 10%. The largest increase was observed in Changhua Chemical, with a financing balance of 54.14 million yuan, up by 29.08% [1][3]. Stocks with Increased Financing Balance - The stocks with significant financing balance increases include: - Changhua Chemical: 54.14 million yuan, +29.08%, closing price 19.90 yuan, +1.38% [3]. - Zhonghuan Hailu: 71.04 million yuan, +23.90%, closing price 21.61 yuan, -5.67% [3]. - Weihai De: 92.84 million yuan, +23.53%, closing price 29.20 yuan, -4.58% [3]. - The average increase for stocks with over 10% growth was 1.85%, with notable performers including Jinkai Biotechnology, Zhaomin Technology, and Haitai Technology, with increases of 16.88%, 14.03%, and 6.96% respectively [1][3]. Stocks with Decreased Financing Balance - A total of 520 stocks experienced a decrease in financing balance, with 12 stocks declining by more than 10%. The largest decrease was seen in Pulaide, with a financing balance of 19.71 million yuan, down by 24.07% [4]. - Other notable declines include: - Jingang Photovoltaic: 33.29 million yuan, -23.39% [4]. - Tianyuan Pet: 68.45 million yuan, -19.54% [4]. Capital Flow Insights - On April 24, among the stocks with increased financing balance, 12 stocks saw net inflows of main funds, with Jinkai Biotechnology leading at 137 million yuan, followed by Jinyang Co. at 66.30 million yuan and Shengyuan Environmental Protection at 32.23 million yuan [2]. - Conversely, 7 stocks experienced net outflows, with Zhaomin Technology leading at 129 million yuan, followed by New Aluminum Era at 74.46 million yuan and Hengbo Co. at 61.49 million yuan [2].

业务评价：公司去年的ROIC为1.51%，资本回报率不强。去年的净利率为7.77%，算上全部成本后，公 司产品或服务的附加值一般。 偿债能力：公司现金资产非常健康。 融资分红：公司上市2年以来，累计融资总额12.17亿元，累计分红总额6882.67万元，分红融资比为 0.06。 据证券之星公开数据整理，近期金凯生科（301509）发布2025年一季报。截至本报告期末，公司营业总 收入1.76亿元，同比上升41.83%，归母净利润4741.78万元，同比上升183.24%。按单季度数据看，第一 季度营业总收入1.76亿元，同比上升41.83%，第一季度归母净利润4741.78万元，同比上升183.24%。本 报告期金凯生科应收账款上升，应收账款同比增幅达77.94%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率51.09%，同比增29.69%，净利率26.89%，同比 增99.7%，销售费用、管理费用、财务费用总计3054.26万元，三费占营收比17.32%，同比减19.29%，每 股净资产18.24元，同比减28.33%，每股经营性现金流0.38元，同比减55.7%，每股收益0.39元，同比增 105. ...

分行业看，今日换手率超20%的个股中，所属基础化工行业个股最多，有6只个股上榜；计算机、汽车 等紧随其后，分别有5只、4只个股上榜。 交易所公开信息显示，今日高换手率创业板股共有8只上榜龙虎榜，买卖居前营业部中，有7股出现机构 身影，恒勃股份有3家机构专用席位上榜，合计净买入3462.25万元，新铝时代有2家机构专用席位上 榜，合计净买入2005.85万元，金凯生科有1家机构专用席位上榜，合计净买入977.19万元，新瀚新材有3 家机构专用席位上榜，合计净买入936.57万元，久祺股份有4家机构专用席位上榜，合计净买入479.44万 元，深股通现身1股龙虎榜，新铝时代获深股通净买入1302.83万元，营业部净买入居前的有天元宠物、 新瀚新材、金凯生科，净买入金额分别为7329.19万元、5686.28万元、3666.89万元，营业部净卖出居前 的是恒勃股份、新铝时代、新天地，净卖出金额分别为6573.16万元、3634.01万元、489.75万元。 资金流向方面，高换手率个股中，有11股今日获主力资金净流入，净流入金额较多的有金凯生科、飞天 诚信、新瀚新材，净流入金额分别为1.37亿元、9893.16万元、9 ...

Group 1 - The Alzheimer's concept sector rose by 1.30%, ranking 6th among concept sectors, with 21 stocks increasing in value [1][2] - Notable gainers in the sector included Jinkai Biotechnology with a 20% limit-up, Shuangcheng Pharmaceutical also hitting the limit-up, and LuKang Pharmaceutical, Fujilai, and Dongcheng Pharmaceutical with increases of 3.95%, 3.60%, and 2.06% respectively [1][2] - The sector experienced a net inflow of 250 million yuan from main funds, with Shuangcheng Pharmaceutical leading the inflow at 181 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Jinkai Biotechnology at 33.12%, Shuangcheng Pharmaceutical at 19.33%, and Chitianhua at 5.51% [3] - The trading volume and turnover rates for key stocks in the Alzheimer's concept were significant, with Shuangcheng Pharmaceutical showing a turnover rate of 23.40% and Jinkai Biotechnology at 23.43% [3] - Decliners in the sector included NuoVizon, Dean Diagnostics, and BGI Genomics, with declines of 2.96%, 2.68%, and 1.85% respectively [1][4]

截至4月24日收盘，CRO概念上涨0.96%，位居概念板块涨幅第9，板块内，38股上涨，金凯生科20%涨 停，双成药业、河化股份、凯莱英等涨停，峆一药业、博腾股份、昊帆生物等涨幅居前，分别上涨 6.50%、5.35%、4.50%。跌幅居前的有星昊医药、康鹏科技、蔚蓝生物等，分别下跌8.43%、4.30%、 3.46%。 今日涨跌幅居前的概念板块 | 业 | | --- | | 603259 | 药明康 | 0.36 | 1.49 | 2800.31 | 1.32 | | --- | --- | --- | --- | --- | --- | | | 德 | | | | | | 300363 | 博腾股 | 5.35 | 5.1 1 | 2230.39 | 5.99 | | | 份 | | | | | | 300725 | 药石科 | 0.38 | 4.14 | 1420.31 | 6.43 | | | 技 | | | | | | 300347 | 泰格医 | 0.35 | 1.99 | 1315.18 | 2.54 | | | 药 | | | | | | | 圣诺生 | | | | | | 688117 | ...

沪指4月24日上涨0.03%，申万所属行业中，今日上涨的有10个，涨幅居前的行业为美容护理、银行， 涨幅分别为1.61%、1.16%。医药生物行业今日上涨0.25%。跌幅居前的行业为计算机、通信，跌幅分别 为2.36%、2.08%。 主力资金净流出的行业有25个，电子行业主力资金净流出规模居首，全天净流出资金66.21亿元，其次 是计算机行业，净流出资金为64.60亿元，净流出资金较多的还有机械设备、通信、汽车等行业。 医药生物行业今日上涨0.25%，全天主力资金净流入2.65亿元，该行业所属的个股共476只，今日上涨的 有243只，涨停的有10只；下跌的有218只，跌停的有3只。以资金流向数据进行统计，该行业资金净流 入的个股有204只，其中，净流入资金超5000万元的有10只，净流入资金居首的是双成药业，今日净流 入资金1.81亿元，紧随其后的是凯莱英、金凯生科，净流入资金分别为1.63亿元、1.37亿元。医药生物 行业资金净流出个股中，资金净流出超3000万元的有9只，净流出资金居前的有花园生物、迈瑞医疗、 智飞生物，净流出资金分别为8240.77万元、6250.66万元、6132.45万元。（数据宝） ...

Market Overview - The Shanghai Composite Index closed at 3297.29 points, above the five-day moving average, with a slight increase of 0.03% [1] - The total trading volume of A-shares reached 1,138.919 billion yuan [1] Stocks Performance - A total of 271 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Jinkai Biological (金凯生科) with a deviation rate of 13.09% and a daily increase of 20.02% [1] - Lusi Co., Ltd. (路斯股份) with a deviation rate of 8.64% and a daily increase of 14.74% [1] - Ketaobiotechnology (科拓生物) with a deviation rate of 8.31% and a daily increase of 11.58% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that just crossed the five-day moving average include: - Daychen Co., Ltd. (日辰股份) [1] - YTO Express (圆通速递) [1] - Jiama Clothing (嘉曼服饰) [1]